CAPTRUST Financial Advisors’s IGM Biosciences IGMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-12,575
| Closed | -$14.1K | – | 2667 |
|
|
2025
Q2 | $14.1K | Sell |
12,575
-733
| -6% | -$895 | ﹤0.01% | 2485 |
|
|
2025
Q1 | $15.3K | Buy |
13,308
+3,107
| +30% | +$5.78K | ﹤0.01% | 2328 |
|
|
2024
Q4 | $62.3K | Hold |
10,201
| – | – | ﹤0.01% | 2222 |
|
|
2024
Q3 | $169K | Buy |
10,201
+1
| +0% | +$11 | ﹤0.01% | 2159 |
|
|
2024
Q2 | $70.1K | Hold |
10,200
| – | – | ﹤0.01% | 2131 |
|
|
2024
Q1 | $98.4K | Buy |
+10,200
| New | +$118K | ﹤0.01% | 2059 |
|
|
2022
Q3 | – | Sell |
-2,750
| Closed | -$50K | – | 3006 |
|
|
2022
Q2 | $50K | Buy |
+2,750
| New | +$49K | ﹤0.01% | 2757 |
|
|
2022
Q1 | – | Sell |
-250
| Closed | -$7K | – | 5008 |
|
|
2021
Q4 | $7K | Hold |
250
| – | – | ﹤0.01% | 3903 |
|
|
2021
Q3 | $16K | Hold |
250
| – | – | ﹤0.01% | 3310 |
|
|
2021
Q2 | $21K | Hold |
250
| – | – | ﹤0.01% | 3074 |
|
|
2021
Q1 | $19K | Sell |
250
-104
| -29% | -$9.47K | ﹤0.01% | 3032 |
|
|
2020
Q4 | $31K | Buy |
+354
| New | +$24.9K | ﹤0.01% | 2052 |
|
|
2020
Q3 | – | Sell |
-100
| Closed | -$7K | – | 3135 |
|
|
2020
Q2 | $7K | Buy |
+100
| New | +$6.08K | ﹤0.01% | 2306 |
|
Other funds holding IGMS
CAPTRUST Financial Advisors's IGMS Position: Q3 2025 in Review
CAPTRUST Financial Advisors sold out of IGM Biosciences (IGMS) in Q3 2025, closing a stake of 12,575 shares — an estimated $14.1K sold.
CAPTRUST Financial Advisors first reported a position in IGMS in Q2 2020 and held it in 13 quarters. The position peaked at $169K in Q3 2024. 1 fund tracked by Wall St. Rank holds IGMS as of Q3 2025.
- CAPTRUST Financial Advisors reported no remaining IGM Biosciences position as of Q3 2025 after selling out during the quarter.
- CAPTRUST Financial Advisors sold 12,575 IGM Biosciences shares in Q3 2025, an estimated $14.1K.
- CAPTRUST Financial Advisors first reported a position in IGM Biosciences in Q2 2020 and held it in 13 quarters.
- CAPTRUST Financial Advisors's IGM Biosciences position peaked at $169K in Q3 2024.
- 1 fund tracked by Wall St. Rank held IGM Biosciences as of Q3 2025.
Based on CAPTRUST Financial Advisors's 13F filing for Q3 2025, filed 19 Nov 2025.